GENERAL ATLANTIC L.P. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 08:13 am Purchase | 2025-03-31 | 13G | Akero Therapeutics, Inc. AKRO | GENERAL ATLANTIC L.P. | 6,796,489 8.400% | 1,562,500 (+29.85%) | Filing |
| 2024-03-15 10:08 am Purchase | 2024-03-06 | 13G | Akero Therapeutics, Inc. AKRO | GENERAL ATLANTIC L.P. | 5,233,989 7.700% | 5,233,989 (New Position) | Filing |